In a statement, Christopher J. Moreau, CEO of Algernon Pharmaceuticals said: “The company welcomes Harry Bloomfield as its newest board member and chairman. His extensive background and years of experience in senior business roles will be a tremendous asset to the company as it moves forward executing its exciting and unique drug repurposing business plan.”
The company noted that Bloomfield is a lawyer, business manager and philanthropist. He began his business career, 1971 to 1976, on Wall Street with the J. Henry Schroder Banking Corporation in New York. From 1981 to 1987 he served as a Member of the Commission des Valeurs Mobilieres du Québec, now called the Autorité des Marchés Financiers – equivalent of the US Securities and Exchange Commission (the SEC).
In 1987 Bloomfield was named by the government of Canadian prime minister Brian Mulroney to the board of directors of the Federal Business Development Bank, now called the BDC (Business Development Bank of Canada (TSX:B of C)) and served for 11 years, seven of which were as chairman of the Audit Committee.
In 1994, in partnership with Bank Julius Baer of Zurich, Switzerland, he formed and was the first chairman of BJB Global Investments, Ltd., a Canadian wealth-management advisory firm with headquarters in Montreal. In 1998, he became the president of the Canadian Branch of the International Law Association.
Bloomfield has served on numerous boards, public and private, including Heller Financial Canada (now part of GE Capital); Banco Comercial Português, the Canadian subsidiary of Sottomayor Bank of Portugal; British Controlled Oilfields, Genoil Inc. (TSX-V:GNO), Balkan Resources Inc., and Wi2Wi Inc. In May 2011, he was elected to the board of directors of Miraculins Inc (TSX-V:MOM)., a medical diagnostic company, and in April 2012 he was elected the board’s chairman.
Algernon is a drug re-purposing company that investigates safe, already approved drugs, and naturally occurring compounds, for new disease applications, moving them efficiently and safely into new human trials, developing new formulations and seeking new regulatory approvals in global markets. The company specifically investigates compounds that have never been approved in the US or Europe to avoid off-label prescription writing.
Contact the author at firstname.lastname@example.org